Literature DB >> 2072697

Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9.

K Yamaguchi1, M Enjoji, M Tsuneyoshi.   

Abstract

A total of 304 patients with pancreatoduodenal carcinoma were studied clinicopathologically and immunohistochemically in order to clarify features of carcinoma of four different sites of origin; carcinoma of the ampulla of Vater (Am), the distal common bile duct (DCBD), the head of the pancreas (PH), and the extra-ampullary duodenum (Du). The mean greatest diameter of 87 PH was 3.5 cm compared with 2.7 cm of 149 Am and 2.7 cm of DCBD. Histopathologically, 40% of Am were papillary adenocarcinoma, while about half of DCBD, PH and Du were tubular adenocarcinoma. PH invaded lymphatic (85%), vascular (62%), and perineural (95%) spaces and metastasized lymph nodes (72%) more frequently than Am (77%, 35%, 24%, 50%), DCBD (47%, 61%, 65%, 45%), and Du (76%, 29%, 35%, 65%), respectively. More than 50% of PH invaded the resected margins, whereas in only 2% of Am, the surgical margins were affected by malignant cells. Immunohistochemically, PH was more frequently positive for both carcinoembryonic antigen (CEA) (98%) and carbohydrate antigen (CA) 19-9 (91%) than Am (83%, 62%), DCBD (94%, 58%), and Du (56%, 11%), respectively. The stromal staining type of CEA and CA 19-9 was more frequently seen in PH (27%, 44%) than in Am (9%, 31%), DCBD (11%, 8%) and Du (0%, 0%), showing a more dedifferentiated nature of PH. The cumulative 3-year survival rate of 87 patients with PH (15%) was worse than that of 149 with Am (42%, P less than 0.001), of 51 with DCBD (25%) and of 17 with Du (58%, P less than 0.001). The survival curve of 87 with PH was worse than that of 51 with DCBD, of 149 with Am (P less than 0.001) and of 17 with Du (P less than 0.001). Cox regression analysis, using eleven profound prognostic variables, revealed that venous invasion, perineural infiltration, surgical margin, and histopathologic type were profound prognostic factors. Pancreatic carcinoma has a more dedifferentiated histopathologic nature, showing a more aggressive growth and fares worse than Am, DCBD, and Du.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072697     DOI: 10.1002/jso.2930470303

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  40 in total

1.  Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases.

Authors:  A Dorandeu; J L Raoul; F Siriser; N Leclercq-Rioux; M Gosselin; E D Martin; M P Ramée; B Launois
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Authors:  Yuan Chen; Shao-An Xue; Shahriar Behboudi; Goran H Mohammad; Stephen P Pereira; Emma C Morris
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

3.  Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer.

Authors:  Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet
Journal:  Hepatogastroenterology       Date:  2012-09

4.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Ritsuko Sawada; Wolfgang W Scholz; Jason S Lewis
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

Review 5.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

Review 6.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer.

Authors:  Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  J Gastrointest Surg       Date:  2008-07-30       Impact factor: 3.452

Review 9.  Therapeutic antibodies for the treatment of pancreatic cancer.

Authors:  Patrick Chames; Brigitte Kerfelec; Daniel Baty
Journal:  ScientificWorldJournal       Date:  2010-06-15

10.  Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore.

Authors:  Thinzar M Lwin; Takashi Murakami; Kentaro Miyake; Paul J Yazaki; John E Shivley; Robert M Hoffman; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2018-01-25       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.